Viemed Q3 Revenue Hits $80.7M, Net Income $4.7M
VMD sits 66% above its 52-week low of $6.05.
Summary
Viemed posted Q3 revenue of $80.673 million, up from $78.1 million in Q2, with gross profit of $46.192 million and net income of $4.737 million. Operating income came in at $6.962 million and pretax profit at $6.785 million, a clear step up from Q2's $2.76 million net income. The quarter shows margin recovery after the prior period's Medicare overpayment charge weighed on the bottom line, though the revenue figure slightly missed estimates. The company also raised the floor of its 2026 revenue guidance, following the August 8-K that reaffirmed 2026 guidance and authorized a new 5% buyback, so the print is the first hard check on that outlook.
At the time of this announcement, VMD was trading at $10.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $385.1M. The 52-week trading range was $6.05 to $12.61. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.